Astrasana Holding AG is introducing its AST-Premium Line, a new range of premium-quality cannabis flowers, to the Swiss market.
The products are already available today in over 20 partner pharmacies across the country. The hand-selected flowers are sourced from carefully chosen cultivars from Thailand, Canada, as well as from Astrasana’s own production facilities in Switzerland.
In an interview, CEO Yves Antoniazzi highlights that the Swiss medical cannabis market has only truly started to take shape since early 2025.
“Our pharmaceutical subsidiary Bogen Pharma AG has been active in the distribution of medical cannabis since 2023. For a long time, however, there was hardly any movement in the market,” he explained.
“By the end of 2024, we were even considering putting the company on hold and focusing on our other business units and exports. But since the beginning of 2025, business has literally taken off; we have seen monthly revenue growth of around 20%.”
The reasons for this sudden growth are not entirely clear to Antoniazzi: “We assume that it simply took time until patients, who until 2022 still required a special federal permit, began making use of the simplified prescription process through their physicians.
With the launch of the AST-Premium Line, Astrasana already offers patients a broad portfolio of around ten different strains and product qualities, with a strong focus on the highest standards and patient benefit.
